登录新浪财经APP 搜索【信披】查看更多考评等级 中经记者 晏国文 卢志坤 北京报道 | ● 信用中国(黑龙江) 首页 | 信用动态 | 政策法规 | 信用承诺 | 信用公示 | 信用服务 | 城市信用 | 专题专栏 | 互动交流 | 站内文章 调输入搜索关键字 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 处罚类别 | | | 吊销许可证件 | | | | | | | | 处罚决定日期 | | | 2025-07-01 | | | | | | | | 处罚内容 | | | | | | | 当事人伪造处方的行为,依据《中华人民共和国药品管理法》第一百二十六条"除本法另有规定的情形外,药品上市许可持 | | | | | | | | | | | 有人、药品生产企业、药品经营企业、药物却临床安全性评价研究机构、药物临床试验机构等未通守药品生产质量管理规 | | | | | | | | | | | 范(GMP)、药品经营质量管理规范(GSP)、药物非临床研究质量管理规范(GLP)、药物临床试验质量管理规范(G | | | | | | ...

在询问笔录中，张某某承认国家医保飞行检查组《飞行检查情况反馈报告》中指出的药店伪造处方销售药品等情 况属实。后该公司采购及相关工作人员陆续配合询问调查。 行政处罚决定书显示，黑龙江思派大药房销售药品中涉嫌伪造处方7869张，根据哈尔滨市医疗保障局行政处罚决 定书（哈医保罚决字〔2025〕第33号），黑龙江思派大药房3194张伪造处方涉及市医保结算，骗取医保基金货值 支出金额1939.07万元，对当事人作出罚款9695.36万元的行政处罚。上述处罚是哈尔滨市医疗保障局5月14日作出 的。 黑龙江思派大药房地址在哈尔滨市南岗区大众嘉园1栋1层5号，位于哈尔滨医科大学肿瘤医院北侧，8月5日中午， 到访该药房的当地人士表示，该药房为闭门状态。 | - 信用中国(黑龙江) | 首页 | 信用动态 | 改策法规 | 信用服务 | 城市信用 | 专题专栏 | 互动交流 | 信用派诺 | 信用公示 | 站内文章 调验入指索关键字 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 处可类别 | 吊销许可证件 | | | | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Sipai Health Technology Co., Ltd. 思派健康科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：0314） 董事會會議召開日期 思派健康科技有限公司（「本公司」）董事會（「董事會」）宣佈，本公司將於2025年8月18日（星 期一）舉行董事會會議，藉以（其中包括）批准本公司及其附屬公司截至2025年6月30日止 六個月的未經審核之中期業績公告，以及考慮派發中期股息（如有）。 承董事會命 思派健康科技有限公司 董事會主席兼執行董事 馬旭廣 香港，2025年8月5日 於本公告日期，本公司董事會包括執行董事馬旭廣先生及李繼先生；非執行董事姚磊文 先生；及獨立非執行董事樊欣先生、何海建先生及黃蓓女士。 ...

Company Overview - Sipai Health Technology Co., Ltd. is a leading medical technology and health management company in China, headquartered in Guangzhou, Shanghai, and Beijing [2] - The company aims to lead the digital transformation of the healthcare industry in China, providing quality and accessible medical services [2] - Sipai operates three business lines: health insurance services, specialty pharmacy business, and physician research assistance [2] Financial Performance - As of December 31, 2024, Sipai Health reported total revenue of 4.565 billion yuan, a year-on-year decrease of 3.11% [1] - The company recorded a net profit attributable to shareholders of -324 million yuan, a year-on-year decrease of 26.57% [1] - The gross profit margin stood at 8.46%, with a debt-to-asset ratio of 46.96% [1] Stock Performance - On July 7, the stock price of Sipai Health closed at 5.19 HKD per share, an increase of 8.35% with a trading volume of 60.082 million shares and a turnover of 311 million HKD [1] - Over the past month, Sipai Health has seen a cumulative increase of 24.74%, but has a year-to-date decline of 12.11%, underperforming the Hang Seng Index by 19.22% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 1.96 times, with a median of 6.18 times [1] - Sipai Health's P/E ratio is -10.28 times, ranking 123rd in the industry [1] - Comparatively, other companies in the industry have the following P/E ratios: Qianjing Pharmaceutical at 0.86 times, Kingsray Biotechnology at 1.43 times, Dongrui Pharmaceutical at 3.06 times, and Jilin Changlong Pharmaceutical at 6 times [1]

Market Overview - On July 2, the Hang Seng Index rose by 0.62%, closing at 24,221.41 points, with a net inflow of HKD 5.036 billion through the southbound trading channel [1] - The total trading volume for the southbound trading was HKD 128.967 billion, with a net buy of HKD 5.036 billion [1] Southbound Trading Details - The Shanghai Stock Exchange's southbound trading had a total transaction amount of HKD 81.984 billion, with a net buy of HKD 1.279 billion [1] - The Shenzhen Stock Exchange's southbound trading had a total transaction amount of HKD 46.983 billion, with a net buy of HKD 3.757 billion [1] Active Stocks - In the Shanghai Stock Exchange's southbound trading, Alibaba-W had the highest transaction amount at HKD 3.170 billion, followed by Chongqing Iron & Steel and Xiaomi Group-W with transaction amounts of HKD 2.929 billion and HKD 2.827 billion, respectively [1] - In terms of net buy amounts, the Yingfu Fund led with a net buy of HKD 1.674 billion, while Alibaba-W had the highest net sell amount at HKD 788 million, closing down by 0.36% [1] Shenzhen Stock Exchange Active Stocks - In the Shenzhen Stock Exchange's southbound trading, Alibaba-W also topped the transaction amount at HKD 2.407 billion, followed by Tencent Holdings and Xiaomi Group-W with transaction amounts of HKD 1.589 billion and HKD 1.582 billion, respectively [2] - The stock with the highest net buy was Innovent Biologics, with a net buy of HKD 651 million, closing up by 1.15%, while Alibaba-W had the highest net sell amount at HKD 945 million, also closing down by 0.36% [2]

Market Overview - On July 2, the Hang Seng Index rose by 0.62%, with southbound funds totaling HKD 128.97 billion in trading volume, including HKD 67.00 billion in buying and HKD 61.97 billion in selling, resulting in a net buying amount of HKD 5.04 billion [1] Southbound Trading Activity - The southbound trading through Stock Connect (Shenzhen) had a total trading volume of HKD 46.98 billion, with HKD 25.37 billion in buying and HKD 21.61 billion in selling, leading to a net buying amount of HKD 3.76 billion [1] - The southbound trading through Stock Connect (Shanghai) had a total trading volume of HKD 81.98 billion, with HKD 41.63 billion in buying and HKD 40.35 billion in selling, resulting in a net buying amount of HKD 1.29 billion [1] Active Stocks - Alibaba-W had the highest trading volume among southbound funds, totaling HKD 55.77 billion, followed by Xiaomi Group-W at HKD 44.08 billion and Chongqing Steel at HKD 37.21 billion [1] - The net buying stocks included 8 companies, with the largest net buying amount for Yingfu Fund at HKD 16.74 billion, followed by Innovent Biologics at HKD 6.51 billion and Meituan-W at HKD 3.38 billion [1] Continuous Net Buying and Selling - Two stocks, namely SMIC and Innovent Biologics, experienced continuous net buying for over three days, with SMIC leading at a total net buying of HKD 59.43 billion and Innovent Biologics at HKD 17.83 billion [2] - The stocks with the highest net selling included Tencent Holdings, Xiaomi Group-W, and Alibaba-W, with total net selling amounts of HKD 22.53 billion, HKD 3.74 billion, and HKD 3.08 billion respectively [2] Summary of Active Stocks on July 2 - The following table summarizes the active stocks with their trading amounts, net buying amounts, and daily price changes: - Yingfu Fund: Trading Amount HKD 1689.30 million, Net Buying HKD 1674.46 million, Daily Change 0.49% - Innovent Biologics: Trading Amount HKD 1079.97 million, Net Buying HKD 651.12 million, Daily Change 1.15% - Meituan-W: Trading Amount HKD 2976.06 million, Net Buying HKD 338.09 million, Daily Change 0.56% - SMIC: Trading Amount HKD 3274.27 million, Net Buying HKD 317.79 million, Daily Change -2.57% - Chongqing Steel: Trading Amount HKD 3720.82 million, Net Buying HKD 144.80 million, Daily Change 91.11% - Xiaomi Group-W: Trading Amount HKD 4408.50 million, Net Selling HKD 36.95 million, Daily Change 0.33% - Tencent Holdings: Trading Amount HKD 3438.30 million, Net Selling HKD 62.96 million, Daily Change -0.30% - Alibaba-W: Trading Amount HKD 5576.67 million, Net Selling HKD 173.65 million, Daily Change -0.36% [2]

Group 1 - On July 2, 2025, Alibaba-W (09988), Chongqing Steel (01053), and Xiaomi Group-W (01810) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 3.17 billion, 2.93 billion, and 2.83 billion respectively [1] - In the Southbound Stock Connect for the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Tencent Holdings (00700), and Xiaomi Group-W (01810) also ranked as the top three, with trading amounts of 2.41 billion, 1.59 billion, and 1.58 billion respectively [1] Group 2 - In the Southbound Stock Connect, the top ten active trading companies included Alibaba-W (09988) with a trading amount of 3.17 billion and a net buy of -788 million, Chongqing Steel (01053) with 2.93 billion and a net buy of 116 million, and Xiaomi Group-W (01810) with 2.83 billion and a net buy of -222 million [2] - The Southbound Stock Connect for Shenzhen-Hong Kong also featured Alibaba-W (09988) with a trading amount of 2.41 billion and a net buy of -945 million, Tencent Holdings (00700) with 1.59 billion and a net buy of -259 million, and Xiaomi Group-W (01810) with 1.58 billion and a net buy of -147 million [2]

Group 1: Market Overview - On July 2, the Hong Kong stock market saw a net inflow of 50.36 billion HKD from northbound trading, with 12.79 billion HKD from the Shanghai Stock Connect and 37.57 billion HKD from the Shenzhen Stock Connect [1] - The most bought stocks included the Tracker Fund of Hong Kong (02800), Innovent Biologics (01801), and Meituan-W (03690) [1] - The most sold stocks were Alibaba-W (09988), Tencent (00700), and Xiaomi Group-W (01810) [1] Group 2: Stock Performance - Alibaba-W had a buy amount of 11.91 billion HKD and a sell amount of 19.79 billion HKD, resulting in a net outflow of 7.88 billion HKD [2] - Xiaomi Group-W had a buy amount of 13.02 billion HKD and a sell amount of 15.25 billion HKD, leading to a net outflow of 2.22 billion HKD [2] - Tencent had a buy amount of 7.39 billion HKD and a sell amount of 11.10 billion HKD, resulting in a net outflow of 3.71 billion HKD [2] Group 3: Sector Insights - The Tracker Fund of Hong Kong (02800) received a net inflow of 16.74 billion HKD, with analysts suggesting that the current market conditions provide a favorable window for investment, particularly in the technology sector [5] - Innovent Biologics (01801) and 3SBio (01530) received net inflows of 6.51 billion HKD and 1.09 billion HKD, respectively, following new measures to support the development of innovative drugs [5] - Meituan-W (03690) saw a net inflow of 3.38 billion HKD, while Alibaba-W and Tencent experienced significant net outflows [6] Group 4: Company-Specific Developments - Chongqing Steel (01053) received a net inflow of 1.44 billion HKD amid rumors of production cuts in Tangshan, which could impact capacity utilization [6] - Pop Mart (09992) received a net inflow of 1.22 billion HKD after being recognized in Time magazine's list of the "100 Most Influential Companies" for 2025 [7] - Xiaomi's Yu7 model orders exceeded expectations, leading to an upward revision of shipment forecasts for 2025 to 2027 [8]

Core Viewpoint - The recent policy measures issued by the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs in China, focusing on various aspects of drug research, access, clinical application, and payment systems [1][12]. Group 1: Policy Impact - The policy includes five specific measures to enhance support for innovative drug development, including increasing research support, integrating innovative drugs into basic medical insurance and commercial health insurance directories, and improving multi-payment capabilities [1]. - The introduction of a commercial health insurance directory for innovative drugs is particularly noteworthy, as it aims to include clinically valuable drugs that exceed basic insurance coverage, thus alleviating financial burdens on patients [15]. Group 2: Market Reaction - Following the policy announcement, the stock of Sipai Health (00314) saw a significant increase, with a peak rise of 49.35% on July 2, reaching a new high of 6.93 HKD, marking a total increase of 105.64% since its low on May 28 [1][5]. - The trading volume of Sipai Health has shown a notable increase, with daily trading volumes frequently exceeding 100 million HKD since late May, indicating strong market interest [2][4]. Group 3: Technical Analysis - Technical indicators suggest that Sipai Health has formed a bullish pattern, successfully breaking through key resistance levels and maintaining a "bullish arrangement" above all important moving averages [6]. - The MACD indicator showed a reversal from a potential bearish signal to a bullish one on July 2, indicating a higher probability of continued price increases [6]. Group 4: Investor Sentiment - Southbound funds have shown a clear interest in Sipai Health, with the holding ratio increasing from 11.57% on May 29 to 14.37% on June 30, reflecting growing demand from mainland investors [7]. - Recent trading data indicates that several institutions have raised their holdings in Sipai Health, with significant purchases from major brokerage firms [10]. Group 5: Competitive Advantage - Sipai Health's unique business model, which integrates medical services management and health insurance, positions it favorably in the market, especially with the new policy measures supporting innovative drugs [15]. - The company's strategic partnerships with various insurance firms and its innovative insurance products provide a competitive edge that is difficult for rivals to replicate in the short term [15].

Group 1 - The core viewpoint of the article highlights a strong performance in the Hong Kong medical sector, particularly with significant gains in stock prices for several companies [1] - Specifically, Sipai Health (00314.HK) saw a remarkable increase of 43%, while MicroPort Medical (00853.HK) rose by 9%, Dingdang Health (09886.HK) by 7%, 3SBio (01530.HK) by 5%, and Innovent Biologics (01801.HK) by 4% [1] - The positive movement in the sector is attributed to the issuance of new measures by the National Healthcare Security Administration and the National Health Commission, aimed at supporting the high-quality development of innovative drugs [1]